HSCT: Donor selection for patients with ALL

Therapy of Ph-positive adult ALL

The role of blinatumomab followed by HSCT in paediatric patients with ALL

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents

Using bioinformatics and genomics to treat AML

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Myeloma highlights from EHA 2019